Cargando…
C1-inactivator is upregulated in glioblastoma
BACKGROUND: Glioblastoma is the most common and aggressive type of primary brain tumor in adults. A key problem is the capacity of glioma cells to inactivate the body’s immune response. The complement system acts as a functional bridge between the innate and adaptive immune response. Still, the role...
Autores principales: | Förnvik, Karolina, Maddahi, Aida, Persson, Oscar, Osther, Kurt, Salford, Leif G., Nittby Redebrandt, Henrietta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589086/ https://www.ncbi.nlm.nih.gov/pubmed/28880870 http://dx.doi.org/10.1371/journal.pone.0183086 |
Ejemplares similares
-
Anti-C1-inactivator treatment of glioblastoma
por: Förnvik, Karolina, et al.
Publicado: (2018) -
Upregulation of C1-inhibitor in pancreatic cancer
por: Osther, Kurt, et al.
Publicado: (2019) -
Combined anti-C1-INH and radiotherapy against glioblastoma
por: Liljedahl, Emma, et al.
Publicado: (2023) -
Evaluating vacquinol-1 in rats carrying glioblastoma models RG2 and NS1
por: Ahlstedt, Jonatan, et al.
Publicado: (2018) -
Long-term anti-tumor effects following both conventional radiotherapy and FLASH in fully immunocompetent animals with glioblastoma
por: Liljedahl, Emma, et al.
Publicado: (2022)